BMS: Retaining Top Talent Through An Acquisition And A Pandemic
Catherine Owen joined Bristol Myers Squibb in September 2019, tasked with overseeing the integration of Celgene and BMS’s international businesses. She talks to In Vivo about managing the merger of teams from two very distinct companies during a global pandemic. Owen, who is passionate about career growth and mentoring, also highlights the importance of talent development and sponsorship – even in times of uncertainty, when business as usual goes out the window.
You may also be interested in...
Successful Leadership In Uncertain Times
In conjunction with In Vivo’s Rising Leaders series, a panel of senior executives representing a wide spectrum of the life sciences industry – from large biopharmaceuticals to small biotech and cancer diagnostics – was convened to discuss what it takes to successfully lead during times of uncertainty and upheaval. Insights on communication strategies, navigating team integrations, supporting diversity and inclusion, and getting the most from multi-generational employees rested on a common theme: valuing people and anticipating workforce needs.
Ovid Therapeutics: Seeking Innovation In Epilepsy Treatment
Rising Leader Julia Tsai wants to see Ovid Therapeutics become a market leading epilepsy company that listens to the needs of patients and develops innovative drugs to treat a spectrum of epileptic indications and symptoms.
Synaffix’s Serial Dealmaker On ADC Platform Success And Expanding Into Gene Therapy
Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.